Actively Recruiting
Pilot Study Evaluating Safety and Effectiveness of NB1 Bone Graft Compared to Autograft in Adults Undergoing Lumbar Fusion for Degenerative Disc Disease
Led by Bone Biologics Corp · Updated on 2026-10-15
30
Participants Needed
2
Research Sites
100 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and initial effectiveness of NB1 Bone Graft in adults aged 17 to 70 who have degenerative disc disease and are undergoing transforaminal lumbar interbody fusion surgery. The study includes participants with up to Grade I spondylolisthesis and involves comparing NB1 at two different doses to the standard autograft treatment. Participants will be randomly assigned to one of three groups NB1 low dose, NB1 high dose, or autograft. The study is conducted across approximately three clinical sites and uses a double-blind design. Treatment involves a single vertebral level spine fusion from L2 to S1. The main focus is on how well bone fusion occurs within 12 months after surgery. During the study, participants will have baseline and follow-up imaging tests including x-rays and CT scans to monitor fusion progress. Researchers will collect data on any adverse events and immune responses. Participants will also complete questionnaires about their quality of life, pain, and function. The study is expected to be completed by December 2028 with primary outcomes assessed at 12 months post-surgery.
CONDITIONS
Brief Title
Evaluation of NB1 Bone Graft Following Lumbar Interbody Arthrodesis
Research Team
B
Brent Atkinson, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here